VivoSeq
Oncology

Cervical Adenocarcinoma

22

Pipeline Programs↗

4

Active Trials↗

16

Companies Involved↗

Cervical Adenocarcinoma is an emerging landscape with 22 programs across 16 companies. The most active players are Bristol-Myers Squibb, Merck & Co., Shanghai Jiatan Pharmatech Co., Ltd. 9 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

0/100

Mech. Concentration

12/100

Completion Rate

50/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2Merck & Co. logo

Merck & Co.

2 programs

Phase 2S

Shanghai Jiatan Pharmatech Co., Ltd

1 program

Phase 2S

Shanghai Pharmaceuticals Holding Co., Ltd

1 program

Phase 2Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

1 program

Phase 2EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

70%

Small molecule

16 of 23 classified programs — the dominant modality here.

30%ALL OTHERSMonoclonal antibody730%

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 23 pipeline programs.

Analysis

Trial Status

7

clinical trials

Recruiting2 · 29%
Not yet recruiting1 · 14%
Unknown status1 · 14%
Terminated1 · 14%
Completed1 · 14%
Active, not recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations
Recruiting·SShanghai Jiatan Pharmatech Co., Ltd·Phase 2·NCT06124963·20 enrolled
IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06654011·25 enrolled
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02257528·26 enrolled
Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma
Not yet recruiting·GGunma University·Phase 2·NCT06805864·45 enrolled
Effectiveness of Prehabilitation on Pelvic Function and Quality of Life Among Post-Surgical Cervical Cancer Women
Completed·Saveetha University·Preclinical·NCT07398313·34 enrolled
A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
Terminated·WWestern Regional Medical Center·Phase 2·NCT02868892·6 enrolled
Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma
Unknown status·WWomen's Hospital School Of Medicine Zhejiang University·Phase 2·NCT05259540·42 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)